Grosset, D. and Grosset, K. (2005) Spheramine Titan/Schering. Current Opinion in Investigational Drugs, 6(7), pp. 722-728. (PMID:16044669)
Full text not currently available from Enlighten.
Abstract
Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Grosset, Dr Katherine and Grosset, Professor Donald |
Authors: | Grosset, D., and Grosset, K. |
College/School: | College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | Current Opinion in Investigational Drugs |
Publisher: | Pharma Press Ltd |
ISSN: | 1472-4472 |
ISSN (Online): | 2040-3429 |
University Staff: Request a correction | Enlighten Editors: Update this record